Sahsen Ventures

Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Insamo is a biotechnology company focused on the discovery and development of membrane-permeable and orally available cyclic peptides, which possess antibody-like binding affinity. Utilizing an automated platform that integrates molecular biology and parallel synthetic chemistry, Insamo aims to rapidly identify preclinical candidates with favorable pharmacological properties. This innovative approach enables the potential replacement of traditional injected or infused biologics with more accessible oral formulations, thereby enhancing patient care. The company's automated design, synthesis, and testing processes allow for unprecedented scalability in the discovery of these therapeutic compounds.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Monod Bio is a life sciences company based in Seattle, Washington, focused on developing innovative biosensors for detecting proteins, toxins, antibodies, and other analytes. Founded in 2021, the company has created a biosensor platform that integrates binding, transduction, and amplification processes in a single step, allowing for the rapid and sensitive detection of a diverse array of target molecules. By leveraging recent advancements in computational protein engineering, Monod Bio has designed highly modular bio-sensing nanoswitches that facilitate cost-effective analytical assays. This technology aims to enhance the capabilities of the healthcare industry in biotechnology and medicine.

Terray Therapeutics is a biotechnology company based in Pasadena, California, founded in 2018. The company specializes in developing innovative treatments for complex human diseases by integrating experimentation and computation to enhance small molecule drug discovery. Terray's unique platform employs ultra-dense microarray technology alongside artificial intelligence and synthetic chemistry to generate extensive and precise chemical datasets. This allows for a rapid design-make-test-analyze cycle, facilitating efficient exploration of chemical space and mapping biochemical interactions between small molecules and disease causes. By utilizing automation and machine learning, Terray addresses significant therapeutic challenges, ultimately guiding the next cycles of drug design and experimentation.

HilleVax is a clinical-stage biopharmaceutical company established in 2021 and based in Boston, Massachusetts. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a vaccine candidate that utilizes virus-like particle (VLP) technology aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Inspire is a patient engagement platform founded in 2005 and headquartered in Arlington, Virginia. The company connects patients and caregivers through a secure, permission-based online website and mobile application. This platform allows members to share and compare their health journeys, fostering a supportive community that enhances the understanding of patient experiences. Inspire's approach facilitates the integration of patient-connected real-world data into pharmaceutical research and product development, ultimately driving breakthroughs in healthcare. By focusing on the patient journey, Inspire aims to advance patient support and contribute to the pharmaceutical industry's innovations.

Elegen is a biotechnology company founded in 2017, focused on developing microfluidic technology to advance synthetic biology. Led by Dr. Matthew Hill, Elegen aims to revolutionize the field by engineering entire genomes and creating innovative DNA synthesizers. Their technology is designed to enhance the speed and efficiency of DNA sequence testing, thereby facilitating significant progress in biomedical research and healthcare applications. Through these efforts, Elegen seeks to contribute to the rapid development of solutions that address various challenges in the life sciences sector.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and addressing neurodegenerative diseases. The company's lead candidate, ATH-1017, is a small hepatocyte growth factor/MET activator designed to penetrate the blood-brain barrier and is currently undergoing various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. Additionally, Athira is advancing other candidates, including ATH-1019, which is in preclinical development for depression, and ATH-1018, aimed at treating peripheral neuropathy. Founded in 2011 and originally named M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its commitment to innovative therapies that positively impact individuals affected by brain disorders.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

TwinStrand Biosciences specializes in advanced DNA sequencing technologies, significantly enhancing the accuracy of mutation detection beyond conventional methods. Their proprietary Duplex Sequencing technology enables the identification of mutations that are often undetectable by standard approaches, making it valuable in various fields such as oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company is dedicated to improving diagnostic capabilities and advancing research through its innovative sequencing solutions. TwinStrand is also involved in biopharmaceutical development, focusing on the discovery and commercialization of biological drugs aimed at treating life-threatening diseases, particularly cancers. Their product pipeline includes recombinant protein-based prodrugs designed for activation by matrix metalloproteinases associated with solid tumors.

Andes develops an integrated microbial technology to help accelerate crop growth. Its technology is combined with artificial intelligence to develop its seeds while reducing input costs and environmental footprints and helps farmers to boost their agricultural output and income. Andes was founded in 2018 and is headquartered in Alameda, California.

Agerpoint, Inc. specializes in providing information management solutions tailored for growers of tree and vine crops, as well as insurers and investors. The company develops advanced technologies to digitize and analyze natural environments, utilizing artificial intelligence and high-performance computing. Through its GroveTracker platform, Agerpoint offers growers critical insights into their crop holdings, including statistical and photographic data on their orchards and vineyards. The company integrates data from various sources, such as drones and satellites, to create precise digital records that enhance decision-making across sectors like agriculture, forestry, and environmental conservation. Founded in 2012 and headquartered in Research Triangle Park, North Carolina, Agerpoint aims to improve the understanding of plants and forests while contributing to efforts against climate change.

NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Variant Bio Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutics through the study of human genetic diversity. Founded in 2018, the company identifies individuals and populations that exhibit extreme traits of medical significance, utilizing advanced sequencing technologies and analytic methods to uncover the genes and pathways associated with these traits. By leveraging insights from genetic research, Variant Bio aims to discover new therapeutic targets for conditions such as neurodegenerative, autoimmune, and cardiometabolic diseases. The company's innovative approach combines statistical genetics and machine learning, enhancing the potential for genomic drug discovery to address unmet medical needs.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, established in 2016. The company specializes in creating performance materials derived from microalgae, focusing on sustainable and high-performance applications. Checkerspot employs advanced techniques in molecular foundry, chemistry, material science, and fabrication technology to develop innovative products, including polyurethanes and textile finish materials. By leveraging the power of biotechnology, Checkerspot aims to expand the range of molecular building blocks available for various industrial applications, providing industries with access to a new generation of sustainable materials.

Impact Vitals is a developer of medical technologies focused on enhancing patient outcomes through advanced monitoring solutions. The company specializes in vital sign monitoring technology that utilizes machine learning to analyze physiological data, offering early warnings of potential health issues. This innovative approach provides healthcare providers with critical insights that facilitate timely interventions, ultimately aiming to lower costs and improve overall patient care. By transforming basic vital signs into actionable information, Impact Vitals contributes to life-saving and life-changing healthcare solutions.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, focused on developing microbiome-based therapeutics for skin diseases. Established in 2014, Azitra leverages its proprietary platform, which includes a microbial library of bacterial strains, to discover and create novel treatments for adverse skin conditions. The company's technology, developed in collaboration with researchers at Yale University and the Jackson Laboratory, is centered around a specific strain of the natural commensal bacteria Staphylococcus epidermidis. Additionally, Azitra employs artificial intelligence and machine learning to enhance the screening and prediction of therapeutic characteristics within its microbial library. By utilizing engineered proteins and live biotherapeutic products for topical application, Azitra aims to advance precision dermatology.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

Lyell Immunopharma Inc is a clinical-stage cell therapy company focused on developing innovative treatments for patients with solid tumors through T cell reprogramming. The company aims to overcome significant challenges in adoptive T cell therapy, specifically T cell exhaustion and loss of durable stemness, which impede effective and lasting responses in cancer treatment. Utilizing its proprietary platforms, Gen-R and Epi-R, Lyell is working to enhance the proliferative capacity, self-renewal, and differentiation abilities of T cells. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, all designed to deliver improved and potentially curative outcomes for patients suffering from solid tumors.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, established in 2016. The company specializes in creating performance materials derived from microalgae, focusing on sustainable and high-performance applications. Checkerspot employs advanced techniques in molecular foundry, chemistry, material science, and fabrication technology to develop innovative products, including polyurethanes and textile finish materials. By leveraging the power of biotechnology, Checkerspot aims to expand the range of molecular building blocks available for various industrial applications, providing industries with access to a new generation of sustainable materials.

Ant Group Co., Ltd. is a leading provider of digital payment and financial services in China, known for its flagship product, Alipay, a widely used digital payments platform. Established in 2000 and headquartered in Hangzhou, the company offers a variety of financial solutions, including Yu'e Bao, an online cash management platform that invests users' funds in a money market fund; Huabei, a consumer credit service facilitating buy now, pay later options; and MYbank, an online bank focused on serving small businesses and entrepreneurs. Additionally, Ant Group operates Xiang Hu Bao, a mutual aid platform for health protection, and Zhima Credit, a credit assessment service for businesses. The company aims to foster digital transformation across the service industry, ensuring that consumers and small enterprises have equal access to inclusive and sustainable financial services. In July 2020, it rebranded from Ant Small and Micro Financial Services Group Co., Ltd. to Ant Group Co., Ltd.

Avail Medsystems, Inc. is a digital healthcare company that develops a platform designed to remotely connect healthcare experts with practitioners. The company's integrated audio/visual hardware and software system facilitates procedural support, observation, and clinical education services, allowing healthcare professionals to collaborate effectively. By enabling real-time access to clinical expertise, Avail aims to eliminate physical, economic, and logistical barriers in the healthcare industry. This approach promotes innovation and enhances the adoption of medical tools and techniques, ultimately improving patient care. Founded in 2017 and based in Palo Alto, California, Avail Medsystems was previously known as Nurep, Inc. and underwent a name change in March 2018.

Neoleukin Therapeutics is a biopharmaceutical company based in Seattle, Washington, founded in 2003. The company specializes in developing immunotherapies for cancer, inflammation, and autoimmune disorders using advanced protein design technology. Their lead product candidate, NL-201, is a de novo protein designed to mimic the therapeutic effects of cytokines interleukin (IL)-2/IL-15, targeting various types of cancer such as renal cell carcinoma and melanoma. Neoleukin Therapeutics leverages computational methods to create custom-designed proteins with enhanced pharmaceutical properties, inspired by natural protein complexes. The company emerged from the University of Washington Institute for Protein Design in January 2019 and was previously known as Aquinox Pharmaceuticals before changing its name in August 2019.

Forterra is a non-profit organization that supports the Pacific Northwest and its wild mountains, rich ecosystems, farmland, small towns, and thriving cities.

PVP Biologics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutic products specifically for celiac disease. Founded in 2015, the company is working on an oral enzyme designed to break down gluten's immuno-reactive components in the stomach. This therapeutic approach aims to alleviate the painful symptoms and intestinal damage that occur from accidental gluten ingestion, thereby improving the quality of life for individuals living with celiac disease. As of early 2020, PVP Biologics operates as a subsidiary of Takeda Pharmaceutical Company Limited, reflecting its commitment to advancing innovative solutions in the field of gastrointestinal health.

TwinStrand Biosciences specializes in advanced DNA sequencing technologies, significantly enhancing the accuracy of mutation detection beyond conventional methods. Their proprietary Duplex Sequencing technology enables the identification of mutations that are often undetectable by standard approaches, making it valuable in various fields such as oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company is dedicated to improving diagnostic capabilities and advancing research through its innovative sequencing solutions. TwinStrand is also involved in biopharmaceutical development, focusing on the discovery and commercialization of biological drugs aimed at treating life-threatening diseases, particularly cancers. Their product pipeline includes recombinant protein-based prodrugs designed for activation by matrix metalloproteinases associated with solid tumors.

SiDx is a health services provider based in Seattle, Washington, focused on modernizing blood group testing to enhance patient care and reduce costs. Founded in 2017, the company has developed a medical device that utilizes micro-sensors on a silicon chip, which are interrogated by laser technology to detect reactivity to various compounds. This innovative diagnostic platform allows healthcare providers to obtain test results during patient visits, thereby expediting the decision-making process and improving overall efficiency in medical testing.

Illumio, Inc. is a cybersecurity company based in Sunnyvale, California, founded in 2012. It specializes in cloud-based security solutions designed to protect organizations from cyber threats and enhance operational resilience. The company's core offering is the Adaptive Security Platform, which includes tools for data center and cloud traffic security. Key components of this platform are the Illumination application traffic mapping tool, the Enforcement application nano-segmentation solution, and SecureConnect for data protection. Illumio's approach centers on Zero Trust principles, helping organizations visualize traffic flows and implement segmentation policies that limit lateral movement within multi-cloud and hybrid infrastructures. This capability is essential for safeguarding critical resources and preventing the spread of cyber attacks. Illumio serves a diverse clientele, including notable companies such as Plantronics, Yahoo, Creative Artists Agency, and NTT Innovation Institute, Inc.

Rocket Pharmaceuticals, Inc. is a biotechnology company dedicated to developing innovative gene therapies for rare and severe pediatric diseases. The company specializes in lentiviral vector and adeno-associated virus platforms to target genetic disorders. Its lead program focuses on treating Fanconi Anemia, a serious condition that leads to bone marrow failure. In addition to this, Rocket is actively researching therapies for several other bone marrow-derived disorders, including Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-I, and Infantile Malignant Osteopetrosis. Furthermore, the company is developing an AAV-based gene therapy for Danon Disease, a multi-organ disorder associated with increased risk of cardiovascular complications. To advance its research, Rocket Pharmaceuticals maintains numerous collaborations and license agreements with prestigious institutions, enhancing its capabilities in gene therapy development. The company is headquartered in New York, New York.

Water1st International is a non-profit organization that provides and supports piped water systems and toilets projects for the world’s poorest communities that improve health, create opportunity, and break the cycle of extreme poverty.

Thorn is an organization focused on combating the sexual exploitation of children through technological innovation. Originally established as the Demi & Ashton Foundation, Thorn collaborates with various stakeholders, including the tech industry, government entities, and non-governmental organizations, to address and disrupt predatory behavior. By leveraging advanced technology, Thorn aims to rescue victims and enhance protections for vulnerable children, thereby creating a safer environment for youth.

MP Materials Corp. is a prominent producer of rare earth materials located in the Western Hemisphere. Founded in 2017 and headquartered in Las Vegas, Nevada, the company owns and operates the Mountain Pass facility, the only large-scale rare earth mining and processing site in North America. This facility is vital to the production of neodymium and praseodymium, which together form neodymium-praseodymium, essential components for magnets used in electric vehicles, drones, wind turbines, and various advanced technologies. MP Materials currently accounts for approximately 15% of global rare earth content, positioning itself as a key player in the industry. The company's integrated operations at Mountain Pass emphasize low production costs while adhering to high environmental standards, reflecting its commitment to sustainability and restoring American leadership in a critical sector.

PoliarisProject is a humanitarian organization that aims to combat human trafficking and modern-day slavery. The organization operates hotlines, policy advocacy programs, client services, advisory services, strategic initiatives, data analysis programs, and global programs to achieve its mission. PolarisProject is based in Washington, D.C.

Amplio offers technology that overcomes barriers like low literacy, local languages, lack of electricity or internet, and traditional gender norms and biases that often limit access to information. With the battery-powered Amplio Talking Book, their partners can deliver hours of local language audio content.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Potlatch Fund is a non-profit organization dedicated to youth development, community building, language preservation and education, and native arts. They also provide training around financial management, board governance, strategic planning, media management, and nonprofit development for past grantees.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Salt Lake City, Utah, that focuses on revolutionizing drug discovery through the integration of advanced technologies such as artificial intelligence, automation, and bioinformatics. Founded in 2013, the company has developed a comprehensive drug discovery platform that includes various tools and software, such as ReChem for chemical compound design, ReScreen for managing complex experimental workflows, and RePredict for modeling drug relationships using machine learning. These innovations enable Recursion to generate extensive biological and chemical datasets, facilitating the exploration of foundational biology and accelerating the development of new therapeutic solutions. Through its unique approach, Recursion aims to significantly enhance patient outcomes and streamline the drug discovery process.

98point6 Inc. is a healthcare technology company that offers on-demand virtual primary care services through its mobile application in the United States. Founded in 2015 and based in Seattle, Washington, the company provides a platform that enables board-certified physicians to deliver personalized consultations, diagnoses, and treatments for both acute and chronic illnesses. Utilizing a text-based interface, patients can receive care anytime and anywhere, allowing for efficient communication regarding their health concerns. The platform is designed to make healthcare more accessible and affordable, empowering physicians to focus more on patient care while leveraging technology to streamline processes such as prescribing medications and ordering lab tests.

Magic Leap is an American startup specializing in Augmented Reality (AR) technology. The company develops proprietary wearable hardware that merges digital imagery with the real world, creating immersive AR experiences indistinguishable from reality. Their innovative Dynamic Digitized Lightfield Signal generates computer-generated 3D images that harmonize with human senses, enabling users to interact with digital devices in a visually cinematic manner. Magic Leap aims to redefine how users access screens and visualize data by combining inherent visual ability with mobile computing technology.

Owl Rock Capital Group, established in 2016, is a New York-based alternative asset manager specializing in credit investments. It caters to the financing needs of middle-market companies in the United States, providing tailored "one-stop" financing solutions across the capital structure. The company invests in senior secured or unsecured loans, subordinated loans, mezzanine loans, and to a lesser extent, equity-related securities and warrants. Owl Rock targets companies with annual EBITDA between $10 million and $250 million and revenue between $50 million and $2.5 billion. Its investment focus spans various sectors, including business services, consumer products, healthcare, industrials, software, and energy, among others. Owl Rock deploys capital through Owl Rock Capital Corporation, a business development company, and is managed by Owl Rock Capital Advisors, a SEC-registered investment adviser. The company's seasoned executives leverage their extensive experience to design and fund custom financing solutions, positioning Owl Rock as a preferred lending partner for middle-market companies and their sponsors.

Uterish operates as an online platform to connect activists, sell feminist apparel, publish an informative monthly newsletter, produce and curate opinionated blog posts, and support Planned Parenthood and the right to bodily autonomy.

Earth Economics identifies and quantifies those benefits to ensure they are included in the decision-making process at all levels.

Fred Hutchinson Cancer Research Center provides research services for the prevention, early detection, and treatment of cancer and other diseases in the United States and other countries. The research center is engaged in researches to prevent, detect, and treat cancer, HIV/AIDS, and other life-threatening diseases. Its activities in the areas of diseases and research cover fundamental research, prevention, early detection, treatment and cures, and survivorships. Researchers of Fred Hutchinson Cancer Research Center pioneered bone-marrow transplantation for leukemia and other blood diseases. This research has cured thousands of patients worldwide and has boosted survival rates for certain forms of leukemia from zero to 85 percent. Fred Hutchinson Cancer Research Center was incorporated in 1971 and is based in Seattle, Washington.

GIRC&D is a community-based organization focused on the prudent use of natural and human resources. Originally sponsored by the U.S. Department of Agriculture and initially administered by the Natural Resources Conservation Service—a federal agency—we are now locally managed. The organization provides many avenues for worthy projects to succeed. Some projects that GIRC&D hosts are finite, but leave a lasting impact. Others become entities and nonprofit organizations on their own. Seven committees outreach to the community; one committee functions internally.

BROTMAN BATY INSTITUTE focuses on basic and applied research in genomics, bioinformatics, and data science to diagnose and cure disease. The Institute was founded in 2017 by philanthropic sponsors Jeff and Susan Brotman, and Dan and Pam Baty in collaboration with UW Medicine, The Fred Hutchinson Cancer Research Center, and Seattle Children’s. The Institute led by Dr. Jay Shendure was formed to accelerate both the basic sciences of precision medicine and the delivery of benefits to patients. The Institute organizes world-renowned investigators in genomics, bioinformatics and data science to share centralized platforms of advanced technologies and equipment in a uniquely collaborative manner. The Institute's aim is to develop insights and knowledge that will more precisely diagnose and treat people with cancer, rare childhood diseases, Alzheimer’s, and other conditions.

AgeneBio, Inc. is a neuroscience pharmaceutical company founded in 2008 by Dr. Michela Gallagher, focused on developing therapeutic products for Alzheimer's disease, dementia, and other memory disorders. The company's primary targets include Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). AgeneBio aims to create innovative therapeutics that prevent neurodegeneration and preserve cognitive function in patients at risk for neurological and psychiatric conditions. By addressing the symptomatic pre-dementia stage of Alzheimer's disease and other related disorders, AgeneBio seeks to provide effective treatments for individuals facing these challenging health issues. The company is headquartered in Indianapolis, Indiana, and engages in global research and development efforts through various partnerships.

TRACON Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of targeted therapies for cancer and wet age-related macular degeneration (AMD). Its lead product, envafolimab, is a PD-L1 single-domain antibody under investigation for soft tissue sarcoma, while other clinical candidates include TRC102, a small molecule in Phase II trials for lung cancer, and TJ004309, a CD73 antibody in Phase I development for advanced solid tumors. TRACON's development pipeline also features TRC253, which is being studied for metastatic castration-resistant prostate cancer. The company employs a capital-efficient, CRO-independent product development platform and actively seeks partnerships with companies outside the U.S. for regulatory and clinical development, as well as commercialization in the U.S. TRACON was founded in 2004 and was previously known as Lexington Pharmaceuticals until its rebranding in 2005.

Roivant Sciences is a biopharmaceutical company dedicated to advancing the development of innovative late-stage drug candidates and enhancing healthcare delivery. The company aims to expedite the process of bringing new medicines to patients while reducing associated costs, thereby benefiting the healthcare system. Roivant achieves this by creating specialized entities known as "Vants," which are agile biotech and healthcare technology companies that leverage unique talent sourcing and incentive alignment strategies. In addition to its focus on biopharmaceuticals, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its commercial-stage drug candidates is VTAMA, a treatment for plaque psoriasis in adults, along with several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, which are at various stages of development.

Adaptimmune Therapeutics, established in 2008, is a UK-based clinical-stage biopharmaceutical company specializing in novel cell therapies for solid tumor patients. Its core technology, the Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform, enables the identification of cancer targets and the development of affinity-enhanced T-cell receptors. Adaptimmune's pipeline includes several SPEAR T-cell therapies in phase I clinical trials, targeting various solid tumors such as urothelial, melanoma, and non-small cell lung cancer. The company has strategic collaborations with GSK, Noile-Immune Biotech, and Universal Cells, Inc. to advance its T-cell therapies.

The mission of the University of Washington Institute for Protein Design is to design a new world of proteins to address 21st century challenges in medicine, energy and technology. The Institute for Protein Design was established in 2012, and is building on strengths within the University of Washington and Seattle more generally. Protein design requires high-level expertise and talent in computing and software, biochemistry, genome sciences, biological structure, pharmacology, immunology and other basic science disciplines, as well as clinical medicine. They are marshaling deep institutional strengths in our faculty, scientific staff, postdoctoral fellows and graduate students, their partners from collaborating institutions, innovator networks, and from the computer and biotechnology industries — bringing extraordinary expertise to bear on a singular focus to advance the potential of protein design. Over the past 16 years, UW researchers have made significant progress in protein design and protein structure prediction, developing the world leading Rosetta software. During this period, UW scientists have developed methods for designing proteins with a wide range of new functions, including catalysts for chemical reactions, HIV and RSV vaccine candidates, and flu virus inhibitors. The IPD integrates these strengths in protein design with Seattle-area expertise in biochemistry, engineering, computer science and medicine, and leverages the exceptional Seattle strength in the software industry.

Landesa is a charitable organization founded in 1967 and based in Seattle, Washington, dedicated to helping impoverished individuals gain legal control over their land. Formerly known as the Center for Women's Land Rights, the organization rebranded in 2010. Landesa collaborates with governments, businesses, and local organizations to secure land rights for vulnerable populations. By ensuring that families have safe land rights, Landesa enables them to invest in their properties, leading to improved agricultural yields and benefits such as enhanced nutrition, health, education, resilience, and overall opportunities for future generations.

Washington Environmental Council is a non-profit organization. To advocate for environmental progress and justice through actions that mobilize the public, elect champions for the environment. They builds power for the environmental movement through community organizing, mobilizing people to speak up on issues as well as attend hearings and other civic engagement opportunities. They also work to educate and train civic activists and support youth-led activists.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.

OCEAN FUTURES SOCIETY works to explore our global ocean, inspiring and educating people throughout the world to act responsibly for its protection, documenting the critical connection between humanity and nature, and celebrating the ocean's vital importance to the survival of all life on our planet.

Amara is an individual and family services organization that drives systemic change, promotes healing, racial, and LGBTQIA+ equity, by offering programs and services to families engaged in foster care, and to adoptees and families, post-adoption.

Plymouth Housing offers permanent homes and support services. They provide adults experiencing homelessness with opportunities to stabilise and improve their lives. They are preserving, developing, and operating safe, supportive housing.

Institute for Stem Cell and Regenerative Medicine (ISCRM) was founded in 2006 at the University of Washington by Tony Blau, Randy Moon, and Chuck Murry. The Institute is working to transform therapies for heart failure, neurodegenerative diseases including Parkinson’s and Alzheimer’s, muscular dystrophy, cancer, diabetes, hearing loss, and retinal, kidney, and liver diseases. Our scientists are conducting research using multiple approaches including pluripotent stem cell technology, gene therapy and precision medicine with the goal of developing novel therapies for diseases where there are few treatments at present.

Imagine a world where people are healthy. There would be less poverty and fewer orphans. There would be stronger economies. There would be hope.Seattle Biomedical Research Institute (Seattle BioMed) was founded at a time when infectious disease research in the U.S. was rare. Our founder had a vision to create a place where the brightest scientists could come together and generate new knowledge and develop innovative solutions to ultimately combat the world’s deadliest diseases. Today that vision is reality. 360 people strong, we're an internationally renowned, non-profit research Institute striving every day to eliminate the world's most devastating infectious disease.

R Baby is the first and only foundation focused on making sure every emergency room is prepared to give babies and children lifesaving care. The organization focuses on the delivery optimal pediatric emergency training, research, treatment, and equipment.

Ashesi University is a private, non-profit liberal arts institution located in Ghana, dedicated to educating ethical and entrepreneurial leaders. Established in March 2002 with a pioneering class of 30 students, the university has rapidly gained recognition for its innovative and high-quality education. Ashesi integrates a liberal arts core curriculum with specialized majors in fields such as computer science, business administration, management information systems, and engineering disciplines. The university aims to cultivate critical thinking skills, a sense of social responsibility, and the courage necessary for students to drive transformation across Africa. Through its commitment to raising the standards of higher education in the region, Ashesi aspires to contribute significantly to a renaissance in Africa.

Math for America is a charitable organization. They offer participation in a professional community, which is critical to sustaining teachers in their careers and attending, designing, and leading courses. It also developed a network of master teacher programs.

The Center for Constitutional Rights is dedicated to advancing and protecting the rights guaranteed by the United States Constitution and the Universal Declaration of Human Rights. Founded in 1966 by attorneys who represented civil rights movements in the South, CCR is a non-profit legal and educational organization committed to the creative use of law as a positive force for social change.

The Canada Green Building Council is involved in the design, construction, and operation of green buildings. They provide the products and services the building sector needs to construct and manage buildings that are easier on resources, healthier for people, and more cost-effective. Their government advocacy efforts help shape the government programs and policies that need to accelerate green buildings, lower carbon emissions, and create equitable communities.

Queens College offers a rigorous education in the liberal arts and sciences under the guidance of a faculty dedicated to both teaching and research. Students graduate with the ability to think critically, address complex problems, explore various cultures, and use modern technologies and information resources.

Pomona College, founded in 1887 and located in Claremont, California, is a prestigious liberal arts institution known for its small class sizes and close student-faculty relationships. The college serves approximately 1,500 students, offering a diverse curriculum that spans the arts, humanities, social sciences, and natural sciences. With a student-faculty ratio of 8 to 1 and an average class size of 15, students benefit from personalized attention from accomplished faculty. Pomona is a founding member of The Claremont Colleges, providing students access to a wealth of resources typically associated with larger universities while maintaining the intimate atmosphere of a small college. The student body is characterized by its extraordinary ethnic and social diversity, enhancing the educational experience. Nestled within an hour's drive of various natural and cultural attractions, Pomona College offers unique opportunities for field study, community engagement, and internships. The college's endowment, amounting to $662 million, supports its mission and academic programs, solidifying its reputation as one of the nation’s premier liberal arts colleges.

Northwest Harvest distributes food to a network of more than 370 food banks, meal programs, and high-need schools throughout Washington State.

Brady works across Congress, courts, and communities to end gun violence.

As the political leader of the pro-choice movement, NARAL Pro-Choice America marshals its resources—the power of people, policy expertise, and political acumen—to make a difference in the lives of women and their families.With more than one million members and supporters, NARAL Pro-Choice America uses the political process to guarantee every woman the right to make personal decisions regarding the full range of reproductive choices, including preventing unintended pregnancy, bearing healthy children, and choosing legal abortion.We are working with the Obama administration and Congress to pursue commonsense solutions, like increasing access to family planning and sex education, and reversing President Bush's anti-choice legacy.

Pesticide Action Network North America is a pesticide and biotech corporation that creates a thriving food system. They grow food, placing the health and economic burdens of pesticide use on farmers, farmworkers, and rural communities. They link local and international consumers and labor into an international citizens action network.

PACIFIC WILDLIFE PROJECT is a humane organization specializing in the rescue and care of wildlife. PACIFIC WILDLIFE PROJECT was Founded in 1985 with the humane goal of wildlife protection and preservation through education, community outreach, and rescue and medical treatment of all wild species.

Galapagos Conservancy is dedicated exclusively to the long-term protection of nature. Galapagos Conservancy is committed to strengthening local institutions and to creating local capacity to ensure the long-term protection of the archipelago.

The Dian Fossey Gorilla Fund is a non-profit organization dedicated to gorilla conservation.